Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 0.79 |
| ▸ | OPRD1 known ✓ | P41143 | 7/20 | 0.78 |
| ▸ | OPRK1 known ✓ | P41145 | 4/20 | 0.78 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.78 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.78 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.78 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.69 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.78 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.69 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8374709 | 0.99 | OPRD1 (0.79) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL14516215 | 0.99 | OPRD1 (0.79) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL16922134 | 0.99 | OPRD1 (0.79) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL149701 | 0.99 | OPRD1 (0.79) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| Hydrochloric Acid SCHEMBL27503745 | 0.98 | OPRD1 (0.78) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL8412616 | 0.93 | OPRD1 (0.75) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL12082104 | 0.93 | OPRM1 (0.80) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL27268268 | 0.92 | OPRD1 (0.68) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL6266395 | 0.91 | OPRD1 (0.67) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| Diacetylmorphine SCHEMBL6566145 | 0.90 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0767663-B1 | COMPOSITION COMPRISING MORPHINE, POLYPYRROLIDONE AND A POLYALKYLENEOXIDE | ALZA CORP (US) | 2002-04-03 | — | — | EP | claimed |
| EP-0767663-A1 | COMPOSITION COMPRISING MORPHINE, POLYPYRROLIDONE AND A POLYALKYLENEOXIDE | ALZA CORPORATION (US) | 1997-04-16 | — | — | EP | claimed |
| US-5593695-A | Morphine therapy | ALZA CORPORATION (US) | 1997-01-14 | — | — | US | claimed |
| WO-1996000066-A1 | COMPOSITION COMPRISING MORPHINE, POLYPYRROLIDONE AND A POLYALKYLENEOXIDE | ALZA CORPORATION (US) | 1996-01-04 | — | — | WO | claimed |
| US-8524277-B2 | Extended release dosage form | ALZA CORPORATION (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110229533-A1 | EXTENDED RELEASE DOSAGE FORM | ALZA CORPORATION (US) | 2011-09-22 | — | — | US | disclosed |
| EP-1600154-B1 | Osmotic extended-release dosage form | ALZA CORP (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100015172-A1 | Method to reduce the physiologic effects of drugs on mammals | ANARCO, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20080063660-A1 | Method to reduce the physiologic effects of drugs on mammals | ANARCO, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080038291-A1 | Method to reduce the physiologic effects of drugs on mammals | ANARCO, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070128279-A1 | Extended Release Dosage Form | ALZA CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
| EP-1600154-A1 | Osmotic extended-release dosage form | Alza Corporation (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6210677-B1 | Method to reduce the physiologic effects of drugs on mammals | CELTIC X LICENSEE LTD. (MT) | 2001-04-03 | — | — | US | disclosed |
| EP-1059916-A1 | EXTENDED RELEASE DOSAGE FORM | ALZA CORPORATION (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999044591-A1 | EXTENDED RELEASE DOSAGE FORM | ALZA CORPORATION (US) | 1999-09-10 | — | — | WO | disclosed |
| US-5667805-A | Morphine therapy | ALZA CORPORATION (US) | 1997-09-16 | — | — | US | disclosed |
| EP-0767663-A1 | COMPOSITION COMPRISING MORPHINE, POLYPYRROLIDONE AND A POLYALKYLENEOXIDE | ALZA CORPORATION (US) | 1997-04-16 | — | — | EP | disclosed |
| US-5593695-A | Morphine therapy | ALZA CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996000066-A1 | COMPOSITION COMPRISING MORPHINE, POLYPYRROLIDONE AND A POLYALKYLENEOXIDE | ALZA CORPORATION (US) | 1996-01-04 | — | — | WO | disclosed |
| US-5460826-A | Morphine therapy | ALZA CORPORATION (US) | 1995-10-24 | — | — | US | disclosed |